Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Keila Bariotto-dos-Santos; Danilo Leandro Ribeiro; Rayanne Poletti Guimar&#227;es; Fernando  Eduardo Padovan-Neto

doi:10.3791/62924

パーキンソン病の片側性6-OHDA病変ラットモデルにおけるL-DOPA誘発ジスキネジアの評価

JoVE Journal
Biology

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Biology

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson’s Disease

パーキンソン病の片側性6-OHDA病変ラットモデルにおけるL-DOPA誘発ジスキネジアの評価

Full Text

3,487 Views

06:45 min

October 4, 2021

DOI: 10.3791/62924-v

Keila Bariotto-dos-Santos*¹, Danilo Leandro Ribeiro*¹, Rayanne Poletti Guimarães¹, Fernando Eduardo Padovan-Neto¹

¹Department of Psychology, Faculty of Philosophy, Sciences and Letters of Ribeirão Preto,University of São Paulo

Please note that some of the translations on this page are AI generated. Click here for the English version.

Overview

This study utilizes the 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease to investigate L-DOPA-induced dyskinesias, aiming to identify therapeutic interventions. The chronic treatment with L-DOPA allows for the assessment of abnormal involuntary movements, providing insights into potential antidyskinetic strategies.

Key Study Components

Research Area

Neuroscience
Pharmacology
Pediatric Medicine

Background

L-DOPA treatment is commonly associated with dyskinesias in Parkinson's disease patients.
Rodent models enable the study of therapeutic effects on dyskinesias.
The 6-OHDA lesion mimics pathophysiological changes seen in human Parkinson's disease.

Methods Used

Stereotaxic administration of 6-OHDA in Sprague-Dawley male rats.
Chronic L-DOPA treatment with benserazide.
Video analysis of abnormal involuntary movements post-treatment.

Main Results

L-DOPA treatment resulted in peak-dose dyskinesias between 30 to 90 minutes.
Patterns of axial, limb, and orolingual movements were systematically scored.
The model effectively mimicked clinical observations of dyskinesias.

Conclusions

This study demonstrates a reliable method to assess L-DOPA-induced dyskinesias.
It underscores the significance of rodent models in developing antidyskinetic therapies.

Frequently Asked Questions

What is L-DOPA-induced dyskinesia?

L-DOPA-induced dyskinesia refers to abnormal involuntary movements that occur as a side effect of long-term treatment with L-DOPA in Parkinson's disease patients.

How is the 6-OHDA model relevant to Parkinson's research?

The 6-OHDA model replicates dopamine depletion seen in Parkinson's disease, allowing for the study of treatments aimed at managing symptoms.

What are the key observations in this study?

Key observations include the timing of dyskinetic movements relative to L-DOPA administration and the assessment of these movements in a controlled environment.

Why is video analysis used in this research?

Video analysis allows for accurate, qualitative scoring of abnormal movements from multiple angles, enhancing the reliability of the observations.

How does this study contribute to antidyskinetic therapy research?

The findings provide insights into the mechanisms and timing of dyskinesias, informing the development of targeted therapeutic interventions.

What implications does this research have for clinical practice?

Understanding dyskinesia onset and severity can guide more effective treatment strategies for Parkinson's patients, improving their quality of life.

Are the animal models used in this study relevant for humans?

Yes, rodent models like the 6-OHDA model have significant predictive validity for human conditions, making them valuable for preclinical research.

L-DOPA誘発性ジスキネジアのげっ歯類モデルは、L-DOPAの反復投与によって現れる発症を弱めたり、症状を緩和したりするための治療的介入を特定するための非常に貴重なツールです。このプロトコルは、パーキンソン病の片側性6-OHDA病変ラットモデルにおいて運動障害様運動を誘発および分析する方法を示しています。

パーキンソン病の6-ヒドロキシドーパミンラットモデルにおけるL-DOPA誘発性ジスキネジアの評価は、効果的な抗運動障害介入を特定するための重要な前臨床ツールです。このモデルは比較的単純で、低コストであり、診療所で起こることと類似しています。この手順は、研究室の博士課程の学生であるダニーロ・レアンドロ・リベイロによってデモンストレーションされます。

体重200〜250グラムのSprague-Dawley雄ラットで実験を開始します。ケージごとに2〜3匹の動物を標準的な実験室条件下で飼育し、食物と水を自由に利用できます。手術の前に、ノルエピネフリントランスポーター阻害剤であるイミプラミンをラット腹腔内に投与します。

View the full transcript and gain access to thousands of scientific videos